Literature DB >> 6345670

The functional significance, distribution, and structure of LFA-1, LFA-2, and LFA-3: cell surface antigens associated with CTL-target interactions.

A M Krensky, F Sanchez-Madrid, E Robbins, J A Nagy, T A Springer, S J Burakoff.   

Abstract

Three cell surface antigens associated with the cytolytic T lymphocyte(CTL)-target cell interaction were identified by generation of monoclonal antibodies (MAb) against OKT4+, HLA-DR-specific CTL and selection for inhibition of cytolysis in a 51Cr-release assay. These MAb block cytolysis by both OKT4+ and OKT8+ CTL and the proliferative responses to PHA and the mixed lymphocyte response (MLR). LFA-1 is an antigen widely distributed on lymphoid tissues and is composed of two polypeptides of 177,000 and 95,000 Mr on all cell types studied. Anti-LFA-1 MAb block NK cell-mediated cytolysis in addition to T lymphocyte-mediated cytotoxicity and proliferation. LFA-2 (Mr = 55,000 to 47,000), a determinant on the sheep red blood cell receptor, is expressed by T cells but not B cells and appears specific for T cell functions. LFA-3 (Mr = 60,000) is a widely distributed antigen present on both hematopoietic and nonhematopoietic tissues and appears to only be involved in T cell functions. MAb to LFA-1 and LFA-2 inhibit function by binding to effector cell surface molecules, whereas anti-LFA-3 MAb appear to block by binding to the target cells. Together with previously described molecules, LFA-1, LFA-2, and LFA-3 demonstrate the complexity of CTL-mediated cytotoxicity at the molecular level.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6345670

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  117 in total

1.  Effect of lengthening lymphocyte function-associated antigen 3 on adhesion to CD2.

Authors:  P Y Chan; T A Springer
Journal:  Mol Biol Cell       Date:  1992-02       Impact factor: 4.138

Review 2.  Antigen presenting cells.

Authors:  D L Hamilos
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

Review 3.  T Cells: Soldiers and Spies--The Surveillance and Control of Effector T Cells by Regulatory T Cells.

Authors:  Bruce M Hall
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-15       Impact factor: 8.237

4.  New monoclonal antibodies in CD44 and CD58: their use to quantify CD44 and CD58 on normal human erythrocytes and to compare the distribution of CD44 and CD58 in human tissues.

Authors:  D J Anstee; B Gardner; F A Spring; C H Holmes; K L Simpson; S F Parsons; G Mallinson; S M Yousaf; P A Judson
Journal:  Immunology       Date:  1991-10       Impact factor: 7.397

5.  Analysis of adhesion molecules in the immunopathogenesis of giant cell arteritis.

Authors:  S O Wawryk; H Ayberk; A W Boyd; J Rode
Journal:  J Clin Pathol       Date:  1991-06       Impact factor: 3.411

6.  Monosaccharide inhibition of cytotoxic T-cell function: demonstration of clone-specific effects.

Authors:  H C O'Neill; C R Parish
Journal:  Immunology       Date:  1988-05       Impact factor: 7.397

7.  Human cytotoxic T-lymphocyte recognition of an HLA-A3 gene product expressed on murine L cells: the only human gene product required on the target cells for lysis is the class I heavy chain.

Authors:  E P Cowan; J E Coligan; W E Biddison
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

8.  Expression of CD2 on porcine B lymphocytes.

Authors:  J Sinkora; Z Reháková; M Sinkora; B Cukrowska; H Tlaskalová-Hogenová; A T Bianchi; B De Geus
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

9.  Human lymphocyte function-associated antigens.

Authors:  A M Krensky; F Sanchez-Madrid; T A Springer; S J Burakoff
Journal:  Surv Immunol Res       Date:  1984

10.  Analysis of different protein kinase C-dependent events in T cells from allogeneic bone marrow transplantation recipients.

Authors:  M A Balboa; M Izquierdo; F Sánchez-Madrid; J M Fernández-Rañada; M López-Botet
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.